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Role of urinary concentrating ability in the generation of toxic
papillary necrosis
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Role of urinary concentrating ability in the generation of toxic papillary
necrosis. We studied the pathogenesis of chemically induced papillary
necrosis in six groups of rats. Papillary necrosis was produced by a
single injection of 2-bromoethylamine hydrobromide (BEA), 50 mg,
iv.; the animals were followed for 7 to 10 days after the administration
of the compound. Following BEA, heterozygous Brattleboro rats
developed all the functional and morphologic lesions of papillary
necrosis that we previously described in Sprague-Dawley rats. They
were unable to maintain sodium balance when dietary sodium was
withdrawn. Homozygous Brattleboro rats, on the other hand, devel-
oped none of the manifestations of papillary necrosis (that is, animals
with central diabetes insipidus were protected completely from the
nephrotoxic effects of BEA). They adapted normally to a zero sodium
diet. Chronic administration of vasopressin to homozygous Brattleboro
rats fully restored the toxic effects of BEA. Lowering urinary concen-
trating ability by inducing a water diuresis in Sprague-Dawley rats
completely protected against BEA-induced papillary necrosis. Decreas-
ing papillary solute concentration by furosemide or increasing urine
flow after abrupt withdrawal of vasopressin to homozygous Brattleboro
rats did not protect against BEA-induced papillary necrosis. We
conclude that the combination, but not either alone, of increased urine
flow and decreased papillary solute concentration protects against the
development of BEA-induced papillary necrosis.
Role du pouvoir de concentration urinaire sur l'apparition d'une
nécrose papillaire toxique. Nous avons étudié la physiopathologie d'une
nécrose papillaire induite chimiquement chez six groupes de rats. La
nécrose papillaire était produite par une injection unique de 2-bro-
moethylamine hydrobromide (BEA), 50 mg, iv.; les animaux étaient
suivis pendant 7 a 10 jours après administration du produit. Après le
BEA, des rats Brattleboro heterozygotes ant développé toutes les
lesions fonctionnelles et morphologiques d'une nécrose papillaire telles
que nous les avions déjà décrites chez des rats Sprague-Dawley. Ils
n'étaient pas capables d'assurer l'equilibre de la balance sodée lorsque
le sodium alimentaire était supprimé. Par ailleurs, des rats Brattleboro
homozygotes n'ont developpe aucune des manifestations de nécrose
papillaire (c'est-à-dire que les animaux ayant un diabète insipide central
étaient complètement protégés des effets néphrotoxiques du BEA). Ils
s'adaptaient normalement a un régime sans sodium. L'administration
chronique de vasopressine a des rats Brattleboro homozygotes a
totalement restauré l'effet toxique du BEA. Le fait d'abaisser la
capacité de concentration des urines en induisant une diurèse aqueuse
dans les rats Sprague-Dawley a complètement protégé contre La nécrose
papillaire induite par le BEA. La diminution de Ia concentration de
solutés papillaires par le furosémide ou l'augmentation du debit urinaire
aprés arrét brutal de la vasopressine chez des rats Brattleboro homozy-
gotes ne protégeait pas contre Ia nécrose papillaire induite par Ic BEA.
Nous concluons que la combinaison, mais non chaque facteur séparé-
ment, d'une augmentation du debit urinaire et dune diminution de Ia
concentration de solutés papillaires protègent contre Ic dCveloppement
d'une nCcrose papillaire induite par Ic BEA.
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Papillary necrosis has been described repeatedly as a major
feature of analgesic nephropathy in humans [1—3]. When stud-
ied in experimental animals, however, salicylates or acetamino-
phen produce papillary necrosis irregularly and only after large
quantities are ingested [4]. Dehydration has been shown to
increase the frequency with which papillary necrosis develops
[5, 61, suggesting that the ability to concentrate the urine may be
important in the generation of drug-induced papillary necrosis.
2-Bromoethylamine hydrobromide (BEA) is a low molecular
weight halogeneated compound which produces complete pap-
illary necrosis in rats. The histologic lesions caused by this
compound were first described by Murray et al [7] and consist
of necrosis of the thin limbs of Henle's loop and collecting duct
as early as 6 hr. Complete papillary necrosis occurs in 7 to 14
days.
We have previously reported the functional changes which
occur over the first 3 days after administration of the compound
[8, 9]. In brief those studies demonstrated that early papillary
necrosis is associated with impaired urinary concentrating
ability, sodium and chloride wastage, potassium wastage on a
low potassium diet, and impaired ability to excrete potassium
following chronic potassium adaptation. Urinary acidification
was normal [81. As assessed by the qualitative Hanssen's
technique, the percent of filtering juxtamedullary nephrons was
decreased [9].
The purpose of this study was to examine the role of urinary
concentration on the generation of chemically induced papillary
necrosis. A variety of animal models were selected in which
urinary concentrating ability, urine flow rate, and papillary
solute concentration were distinctly abnormal. Morphology and
the adaptation to a zero sodium diet were studied for 7 to 10
days after the administration of BEA.
Methods
Balance studies
Group 1 - hererozygous Brattleboro rats. A pair of heterozy-
gous Brattleboro rats was mated repeatedly at our institution
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over a I-year period. Urine osmolality was measured on 4
consecutive days to separate the heterozygous Brattleboro rats
from their homozygous litter mates. Animals with a urine
osmolality greater than 1200 mOsm/kg H20 were considered
heterozygotes (group 1) while those with a urine osmolality less
than 400 mOsm/kg HO were placed in the homozygous groups
(groups 2, 3, and 5).
Twelve male heterozygotes, weighing 237 to 306 g, were
placed in metabolic cages. The animals were allowed to adjust
to the cages for 3 days prior to the beginning of the study. They
were fed 20 g/day of regular powdered rat chow and were
allowed free access to water. Three consecutive 24-hr urine
collections were made for urine osmolality and excretion of
sodium and creatinine. Fluid intake and weight were measured
daily.
The animals were randomized and anesthetized with Keta-
mine (10 mg/lOO g body weight, i.p., Parke-Davis, Morris
Plains, New Jersey). Papillary necrosis was produced by a
single intravenous dose of 50mg BEA in six animals. Six were
sham injected with an equivalent volume of the diluent (O.97c
NaCl). Three consecutive 24-hr urine collections were obtained
as previously described. The animals were then placed on a
zero sodium diet, and urine collections were obtained for the
subsequent 6 days. The animals were sacrificed 9 days after
BEA.
At the end of the experimental period the animals were again
anesthetized with Ketaniine. Arterial blood was obtained for
plasma electrolytes, osmolality. blood urea nitrogen, and creati-
nine. The kidneys were removed and fixed in formalin for light
microscopy.
Group 2 — homozygous Brattlehoro rats. Fourteen male
homozygous Brattleboro rats were studied in a manner identical
to their litter mate heterozygotes (that is, group 1). The animals
were sacrificed 9 days after BEA.
Group 3 - homozygous Brattlehoro rats, t'asopressifl re-
p/aced. Twelve male homozygous Brattleboro rats were given
daily injections of vasopressin tannate in oil (I mU. i.m.)for 9
days. Urine osmolality was checked prior to vasoprcssin and
again after day 9 just prior to the beginning balance of the
period. The animals were placed in metabolic cages, allowed
free access to water, and the protocol outlined in group I was
followed. Vasopressin was given as above for the remainder of
the study. The animals were sacrificed 9 days aftcr administra-
tion of BEA.
Group 4 - nater diuresi.s in Sprague-Dawlev rats. Fourteen
male Sprague-Dawley rats weighing from 250 to 300 g were
allowed free access to 5% glucose drinking solution for 9 days.
Urine osmolality was checked prior to the administration of
glucose and again 9 days later. The animals were then placed in
metabolic cages and the protocol as outlined in group 1 was
followed, except that 5% glucose was used as the drinking fluid.
The animals were sacrificed 9 days after BEA.
Group 5 - abrupt t'asopressin withdrawal in homozvgous
Brattleboro rats. Four male homozygous Brattleboro rats were
treated with daily injections of vasopressin for 10 days as
previously described. Urine osmolality increased to 1550 43.8
mOsm/kg H20 and urine volume was 7.6 2.5 mI/day. Vaso-
pressin was abruptly withdrawn, and urine volume was allowed
to increase over a 36- to 48-hr period. The animals were
followed as described for group 1 (H,O as drinking fluid) except
PN,,. mEq//irer 132.5 * 7.4 NS 144.2 I.!
PK. mEq liter 4.88 0.49 NS 3.80 0.3!
P1, inEqiliter 90.5 8.7 NS 04.5 0.6
BUN, ,ng'/r 169.8 85.8 0.05 13.1 1.3
P,. mgV 2.48 1.09 0.05 0.66 0.02
Cumulative UNV.
tnEq/6 days 5.21 t).72 0.05 2.85 0.26
Urine volume, tnt day 41.5 3.3 0.05 12.2 1.2
U, ,nO,sm/Ag H20 631 31 0.0! 1723 37
Initial weight, g 29! 2 NS 300 + 25
Change weight 15.6 4.0 0.01 3.0 1.6
N 6 6
that all five animals in this group received BEA. The animals
were sacrificed after 4 days on a zero sodium diet (7 days after
BEA).
Group 6 — chronic jurosemide administration to Sprague—
Dan'ley rats. Group 6a. Twelve male rats were placed on
chronic furosemide (15 mg/kg/day) and allowed free access to
regular chow for 9 days. Urine osmolality decreased to 467 51
mOsm/kg H20. The furosemide was withdrawn on the day prior
to the administration of BEA, and water was administered as
the drinking fluid. Six animals were given BEA and six animals
received the diluent. The animals were placed in metabolic
cages and treated as described in group I. The animals were
sacrificed after 4 days on a zero sodium diet (7 days after BEA).
Group oh. Papillary tissue from five control animals and five
chronic furosemide animals (treated as described in group 6a)
was analyzed for osmolality and solute concentration after 9
days of regular diet and access to either H20 or furosemide. On
day 10 which was equivalent to the day of BEA administration
they were sacrificed. Osmolality and solute concentration was
determined according to the method described by Gilbert et al
[101. Osmolality in the papillary homogenate was calculated by
the equation, Osm 1.86 (Na + K) + urea.
Light microscopy
At the end of each experiment the kidneys from the six
groups were coded and placed in buffered formalin for light
microscopy. Sagittal sections from cortex to papilla, approxi-
mately l0-c thick, were made and stained with hematoxylyn
and eosin. The coded specimens were read by a renal
pathologist.
Analytical methods
Plasma and urine electrolytes and creatinine were measured
as previously described [II]. Urine osmolality was measured
using a vapor pressure osmometer (Wescor, Inc., Logan,
Utah).
All results are expressed as X SEM. Statistical analysis was
performed using the unpaired t test with significance chosen at
P < 0.05.
Diets
Powdered rat chow was obtained from the Biological Re-
search Laboratory, the University of Illinois, Chicago, Illinois.
The regular rat chow comprises a complete diet containing 27%
Table 1. Group 1: Arterial electrolytes and cumulative sodium
excretion in heterozygous Brattleboro rats
BEA P< Sham
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Fig. 1. Mean sodium excretion in BEA- (A, closed triangles) and sham-(•, closed circles) injected heterozygous Brattleboro rats (group 1).
BEA was administered after day 3 on regular rat chow; sodium was
withdrawn after day 6. Asterisks (*) indicate a significant difference
from control (P < 0.05).
protein, 59% starch, 10% vegetable oil, and vitamins. The diet
also contains 1.5 mEq sodium, 2.7 mEq potassium, and 1.5
mEq chloride per 10 g.
The zero sodium diet was obtained from ICN Nutritional
Biochemical, Cleveland, Ohio. The powdered diet is a sucrose-
and casein-based diet containing 5% of a sodium-free mineral
mixture fortified with vitamins. The potassium and chloride
content of the diet was similar to the regular rat chow.
Results
Group I - heterozygous Brattleboro rats. Table 1 shows the
arterial electrolytes in the sham- and BEA-injected heterozy-
gous Brattleboro rats at the end of the experimental period.
Plasma sodium, potassium, and chloride were not different in
the two groups of animals. Plasma creatinine and BUN was
higher in BEA-treated animals.
Figure 1 illustrates the pattern of sodium excretion in the
sham- (open circles) and BEA-treated animals (closed circles).
Following the administration of BEA, cumulative sodium ex-
cretion was significantly higher than in sham-injected animals
during the first 72 hr on a regular sodium diet as we have
described previously [9]. As shown in Table I, when placed on
a zero sodium diet, sham-injected animals came into balance
over the 6-day period excreting a virtually sodium-free urine.
By contrast, cumulative sodium excretion was significantly
higher than sham-injected controls.
Light microscopy revealed papillary necrosis extending from
the tip of the papilla to the base with virtually a total loss of cell
architecture. Some areas of cellular infiltration were seen. The
superficial cortex appeared normal.
Table 2. Group 2: Arterial electrolytes and cumulative sodium
excretion in homozygous Brattleboro rats
PNa, mEqlliter
PK, mEqlliter
Pci, mEq/liter
BUN, mg%
PCr, mg%
Cumulative UNaV,
mEq/6 days
Urine volume, mI/day
Uosm, mOsm/kg H20
Initial weight, g
% Change weight
N
BEA P< Sham
148.5 1.1 NS 146.1 3.2
3.70 0.66 NS 4.13 0.23
116.0 1.1 NS 116.0 3.5
23.9 2.5 0.05 12.8 2.0
0.78 0.02 0.05 0.55 0.06
Table 3. Group 3: Arterial electrolytes and cumulative sodium
excretion in vasopressin-replaced homozygous Brattleboro rats
BEA P< Sham
PNa, mEqlliter 119.3 3.9 0.01 138.4 1.5
Pci' mEq/liter 85.8 2.7 0.01 100.3 2.3
BUN, mg% 174.0 50.3 0.001 22.5 2.5
PCr, ing% 2.40 0.53 0.05 0.79 0.15
Cumulative UNaV,
mEq/6 days 4.1 0.4 0.05 1.8 0.3
Urine volume, mi/day 37.1 1.0 0.05 12.6 1.7
U0, mOsm/kg H20 517 46 0.01 1840 106
Initial weight, g 244 7 NS 237 12
% Change weight —24.0 2.5 0.01 —2.6 4.0
N 7 7
Group 2 - homozygous Brattleboro rats. To further examine
the role of urinary concentration and vasopressin on the genera-
tion of papillary necrosis, BEA was injected into six homozy-
gous Brattleboro rats. Six animals were sham-injected. The
balance protocol as outlined for group 1 was followed.
Table 2 shows the arterial electrolytes after 7 days on a zero
sodium diet. There was no difference in plasma sodium, potassi-
um, and chloride between the two groups. Plasma creatinine
was 0.71 0.02 versus 0.55 0.06 mg% in BEA- and sham-
injected animals, respectively (P < 0.05). BUN was slightly,
though significantly, higher in BEA-treated animals. Urine
osmolality was the same in both groups of animals. When
placed on a zero sodium diet 3 days after BEA, there was no
significant difference in the pattern of sodium excretion be-
tween the two groups of animals.
A saggital section of the papillary tip revealed that the
epithelial lining of the papilla was intact. Except for mild
leukocytic infiltration, a normal papilla was seen 10 days after
the administration of BEA.
Group 3 - homozygous Brattleboro rats, vasopressin re-
placed. Daily injection of vasopressin to 14 homozygous Brat-
tleboro rats caused an increase in urine osmolality from 222
23 to 1898 45 mOsm/kg H20 (P < 0.001). The animals were
then randomly divided into two groups and placed in metabolic
cages. Urine sodium excretion was 1.5 0.2 versus 1.3 0.1
mEq/day for 3 days prior to injection of BEA in the sham and
experimental groups, respectively (NS). BEA was given to one
half of the animals and they were observed in the same manner
as group 1.
Table 3 illustrates the arterial electrolytes, cumulative sodi-
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Fig. 2. Mean sodium excretion in BEA- (A, closed triangles) and sham-
(•. closed circles) injected Sprague-Dawlev rats undergoing 5% glu-
cose diuresi.s (group 4). BEA was administered after day 3 on regular rat
chow: sodium was withdrawn after day 6. There was no statistical
difference between the two groups of animals.
urn excretion, and urine osmolality in the BEA- and sham-
injected animals followed for 6 days after the withdrawal of
dietary sodium. BEA-injected animals had severe hyponatre-
mia and hypochloremia as compared to sham-injected animals.
This is probably due to a combination of excessive water
retention secondary to vasopressin, as well as the renal failure
induced by BEA. Plasma creatinine was significantly higher in
BEA-injected animals as compared to controls. BEA-injected
animals develop a concentrating defect as we have described
previously [8, 91. After placing all the animals on a sodium
deficient diet, cumulative sodium excretion was higher in BEA-
treated animals. Thus, vasopressin-replaced homozygous
Brattleboro rats, when given flEA, were unable to reach
sodium balance.
Light microscopy performed at the end of the study revealed
severe papillary necrosis in every BEA-injected animal. The
juxtamedullary region revealed total loss of the papillary struc-
tures, cellular infiltration, vacuolization, and librinous debris in
the lumen of the thin limbs of Henle's loop.
Group 4 - Sprague-Dawlev rats with wafer diuresis. To
further evaluate the role of urinary concentrating ability on the
generation of flEA-induced papillary necrosis, 12 Sprague-
Dawley rats were given 5% glucose as their drinking fluid 9 days
prior to study. Urine osmolality was 1250 161 mOsm/kg H20
prior to initiating a water diuresis (N — 12).
Figure 2 illustrates the pattern of sodium excretion following
the withdrawal of dietary sodium. Over the 6 experimental days
both groups of animals (BEA- and sham-injected) were able to
reach sodium balance in a completely normal fashion. This
Table 4. Group 4: Arterial electrolytes and cumulative sodium
excretion Sprague-Dawley rats given 5% glucose
BEA P< Sham
PNa, mEq//iter
PK, mEg/liter
Pc, mEq/liter
PgIUco..e. mg%
BUN, mg%
U,,,, mOssn/kg H20
Cumulative UN.,V.
mEq/6 day
Initial weight, g
% Change weight
Urine volume, mi/day
N
Table 5. Group 5: Plasma electrolytes and urinary sodium excretion
following abrupt withdrawal of vasopressin to Brattleboro rats
PN,, mEq/iiter 140.6 11.4
PK, mEg/liter 7.2 2.1
Pci, ,nEq/iiter 102.3 9.8
U,,,,,, ,uOsrn/kg H,O 313 64
BUN, sng% 183.8 86.8
Pr.,, mg% 2.67 0.83
Cumulative UNaV, mEq/4 day,s 4.1 0.6
N
pattern was similar to that seen with the homozygous Brattle-
boro rats given BEA (that is, group 2).
Table 4 shows the arterial electrolytes, blood urea nitrogen,
and cumulative sodium excretion in the two groups of animals
at the end of the study. There was no difference in plasma
sodium, potassium, glucose, or blood urea nitrogen. Urine
osmolality, following BEA was unchanged from control. Cumu-
lative sodium excretion was the same in both groups following
the withdrawal of dietary sodium.
Light microscopy performed at the end of the study revealed
an intact papilla in every animal. There was some evidence of
cellular infiltration noted: however, otherwise the histology was
completely normal.
Group 5 - abrupt withdrawal c(f' vasopressin inhomozygous
Brattleboro rats. Vasopressin was given to four rats to restore
urine concentration and urine Ilow to normal. This maneuver
has been shown to also restore papillary solute concentration
112, 131. Vasopressin was then abruptly withdrawn, and after
the urine flow rate had increased (36 to 48 hr later), the animals
were given BEA. Prior to administration of BEA, urine osmo-
lality was 1550.2 43.8 mOsm/kg H20, and urine volume was
7.6 2.5 ml/24 hr. Urine volume increased to 52.0 8.4 ml/24
hr when the BEA was given. Plasma electrolytes of the four
animals are shown in Table 5. Plasma creatinine and BUN rose
in a manner similar to group 1. Furthermore, these animals
were unable to excrete a sodium-free urine when placed on a
sodium-deficient diet. Weight loss in these animals was 41.5
3.2%.
All animals had histologic evidence of papillary necrosis.
Thus, it appears that a rise in urine flow rate alone is not
protective against this form of papillary necrosis.
Group 6 - chronic Ji,ro.semide administration to Sprague-
Dawley rats. This group of animals was studied to assess
900
800
700'
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C0
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E
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147.3 2.3 NS 146.5 * 1.8
3.80 0.25 NS 4.08 0.11
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19.6 + 3.8 NS 12.0 1.2
170 NS 266 --23
0.8 0.3
300
15.5 4.8
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6
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4
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Table 6. Papillary solute concentration
Control = 174.1 45.4 unmeasured osmoles.
b Furosemide = 82.1 16.5 unmeasured osmoles.
Table 7. Group 6: Arterial electrolytes and cumulative sodium
excretion in chronic furosemide-treated Sprague-Dawley rats with and
without BEA
BEA P< Sham
PNa, mEqiliter 140.1 6.1 NS 144.6 0.8
PK, mEqiliter 4.7 0.6 0.05 3.0 0.2
Pc, mEqiliter 93.3 4.4 NS 94.6 ÷ 2.6
BUN, mg% 159.3 55.1 0.05 31.8 3.8
PCr, mg% 3.3 0.0 0.05 0.63 + 0.05
Cumulative UNaV,
mEq/4 day 3.1 + 0.5 0.05 1.0 + 0.2
U0,, mOsm/kg H20 379 47 NS 401 10
Initial weight, g 316 18 NS 320 + 11
% Weight —15.4 1.4 NS —12.8 1.2
whether or not a fall in papillary solute concentration with
normal urinary flow rate would affect the generation of papillary
necrosis. Five animals were sacrificed at the same time that
BEA was given to group 6a animals to determine the papillary
solute concentration (group 6b). These data are shown in Table
6. As shown, there is a low papillary concentration of sodium,
potassium, and urea as compared to control. Twenty-four hour
urine volume was 6.8 1.2 versus 10.6 3.3 ml in control and
furosemide-treated animals, respectively (NS). After zero sodi-
um diet the BEA-treated animals (group 6a) continued to waste
sodium as compared to controls (Table 7). Cumulative sodium
excretion, plasma BUN, and creatinine was higher in the BEA-
treated animals.
Each animal in the BEA-treated group had histologic evi-
dence of papillary necrosis. Thus, a loss of papillary solute
alone does not protect against this form of papillary necrosis.
Discussion
The administration of a single dose of BEA causes papillary
necrosis in virtually 100% of the treated animals [7—91. The
mechanism responsible for this effect has not been elucidated
clearly, but it may be secondary to a direct toxic effect of this
compound on the renal tubular cells or renal interstitium. Since
this effect is selective for the renal papilla it is also likely that
the agent is concentrated in the renal papilla where it achieves
concentrations high enough to exert its toxic effect. If this was
the mechanism responsible for the papillary necrosis seen
following administration of this agent, then maneuvers which
alter the concentrating capacity of the kidney might exert a
protective effect.
The initial observation made in this study was that adminis-
tration of the usual toxic dose of BEA to animals with central
Urea Calculated
mmo/eslkg Osm (mOsmIkgH2O)
149.1 809.6a
--51.8
0.05 0.05
diabetes insipidus, that is, homozygous Brattleboro rats, result-
ed in minimal or no toxicity. These animals did not develop a
typical histologic picture of papillary necrosis and were also
able to conserve sodium when placed on a zero sodium diet.
This is in sharp contradistinction to the observations made in
heterozygous Brattleboro rats identically treated. These ani-
mals, rats which have endogenous vasopressin and are able to
concentrate the urine normally, developed the full blown pic-
ture of papillary necrosis and its functional counterpart, sodium
wastage. It is possible, however, that a larger dose of BEA
might induce papillary necrosis in rats with central diabetes
insipidus.
That the protective effect observed in the homozygous Brat-
tleboro rats was the consequence of vasopressin deficiency was
demonstrated by the experiments in which vasopressin was
administered to these animals. Prolonged vasopressin adminis-
tration resulted in a complete restoration of normal concentrat-
ing capacity. At this point the administration of BEA produced
papillary necrosis. Furthermore, the administration of glucose-
containing drinking water to Spraque-Dawley rats resulted in a
high rate of urine flow and a low urine osmolarity when
compared to control animals. This functional state is similar to
that observed in central diabetes insipidus and was also associ-
ated with virtually complete protection from the nephrotoxic
effect of BEA. Thus, it seems quite clear that animals elaborat-
ing a dilute urine in increased amounts do not develop papillary
necrosis when BEA is given.
The animals with central diabetes insipidus and the glucose-
drinking rats have a functional alteration, when compared to
normal hydropenic rats, which consists of two parts. The
elaboration of a dilute urine for prolonged periods of time is
associated with a decrease in the papillary solute gradient [12,
131. Furthermore, these animals have a high rate of urine flow.
Thus, it is possible that the protective effect we observed was
the consequence of a high rate of urine flow, a decrease in
papillary osmolarity, or combination of the two. To dissect
these possibilities we performed additional experiments. Furo-
semide was given on a chronic basis. This resulted in a decrease
in papillary osmolarity (Table 6). At this point the furosemide
was withdrawn and BEA was administered. In other words, the
compound was given to animals with a decreased papillary
osmotic gradient but with a normal rate of urine flow. As is
clearly demonstrated in Table 7, the presence of a reduced
osmotic gradient in the renal papilla exerted no protective
effect.
To examine the other variable, an increase in urine flow
without a prolonged decrease in papillary tonicity, we studied
Measured Na K
Osm (mOsmlkg H20) mEq/liter rnEq/liter
Control
N= 5
P<
Furosemide-treated
N= 5
295.8
35.4
987.2
64.4
0.05
284.8
27.3
59.3
0.05 0.05
41.0 16.6 97.6
23.0
204. 5b
±39.6
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the effect of abrupt withdrawal of vasopressin to vasopressin-
replaced Brattleboro rats.fhis maneuver resulted in a sudden
increase in urine volume on the background of a previously
normal papillary osmotic gradient. Again, as seen in Table 5, no
protective effect was observed. Thus, it is clear that to prevent
the nephrotoxic effect of BEA, both a prolonged increase in
urine flow and a decreased papillary solute gradient must be
present. Or, for BEA to exert its toxic effect either a reduced (in
essence, a normal) rate of urine flow must be present or a
normal papillary osmotic gradient must be present. The exact
interrelationship between these two variables in the causation
or prevention of this lesion remains to be elucidated. In
addition, vasopressin may play a role in the pathogenesis of this
lesion through a mechanism unrelated to urine flow or papillary
tonicity.
While there are obvious differences between BEA-induced
papillary necrosis and its human counterpart, there may be
some relationship between the results reported in this study and
analgesic nephropathy. Several investigators have reported that
analgesic-induced papillary necrosis was more severe in experi-
mental animals that were volume-contracted [5, 6]. Clinical
anecdotes and epidemiologic studies have long held that well
hydrated patients are less prone to the nephrotoxic properties
of analgesics than their less well hydrated counterparts [14].
These observations in humans combined with ours using the
BEA model in rats suggest that a concentrated urine is impor-
tant, or indeed required, in the pathogenesis of drug-induced
papillary necrosis. Furthermore, salicylates, compounds impli-
cated as causing papillary necrosis in humans, are concentrated
preferentially in the innermost portions of the kidney [15, 18].
Likewise, acetaminophen is concentrated in the urine during
antidiuresis [191. Concentrations within the renal medulla under
these conditions are five to seven times higher than those seen
in the cortex. It has been postulated that the intrarenal gradient,
allowing concentration of these drugs in the deeper structures
of the kidney, is the mechanism responsible for the toxic effects
of these compounds (for review, see [20]).
Regardless of the relationship between our studies using BEA
and analgesic nephropathy in humans, it is quite clear that an
intact concentrating mechanism in the rat kidney is required for
the expression of BEA nephrotoxicity using a single dose. The
presence of either intact papillary osmotic gradient or a relative-
ly reduced rate of urine flow allows the compound to cause
papillary necrosis. The combination of a high rate of urine flow
and reduced papillary tonicity prevents BEA nephrotoxicity
most likely because it prevents accumulation of a sufficient
amount of the agent within the papilla to cause necrosis. These
observations may have clinical relevance.
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